UCB acquires Candid Therapeutics

UCB has reached an agreement to acquire biotechnology firm Candid Therapeutics in a transaction valued at up to $2.2 billion. The acquisition aims to strengthen UCB's immunology pipeline by incorporating Candid's advanced T-cell engager technology. This deal includes a $2 billion upfront payment and an additional $200 million contingent on future milestone achievements. The transaction, pending regulatory approval, is slated to close by mid to late 2026.

The acquisition’s centerpiece is cizutamig, a bispecific antibody that aims to address both oncological and autoimmune conditions by targeting BCMA and CD3 proteins. The drug is designed to deplete BCMA-expressing plasma cells and B-cells while mitigating the risk of cytokine release, a common concern in T-cell engager therapies. Cizutamig is under clinical evaluation in over 10 autoimmune indications and has shown encouraging results in treating more than 100 patients. Additionally, an active Phase I trial is underway, specifically assessing its application in refractory seropositive rheumatoid arthritis.

For UCB, this acquisition represents a calculated move to broaden its offerings in next-generation immunology. The inclusion of Candid’s T-cell engager cizutamig complements UCB's existing assets and aligns with its multi-antigen strategy for immune modulation. The deal follows UCB’s recent acquisition of the ATG-201 CD19 TCE, which signaled its commitment to diversifying its approach to B-cell lineage targets.

With the biotech sector becoming increasingly competitive, this acquisition could position UCB favorably against its peers. By enhancing its immunology franchise through an advanced bispecific antibody, UCB seeks to differentiate itself in the crowded biologics market. This strategic acquisition underscores the growing emphasis on multi-specific T-cell engager therapies to achieve more comprehensive disease control.

Looking ahead, UCB will need to navigate regulatory approvals and manage integration to realize the potential of Candid’s technology. The company's expectations of managing the financial impact within its current framework suggest confidence in both the transaction's justification and the anticipated growth trajectory projected in high single to low double-digit revenue for 2026. The closing of this deal will mark a significant step in UCB's strategy to reinforce its position in the targeted immunotherapy space.